Resaphene Suisse AG / Key word(s): Delisting
Resaphene Suisse AG: Resaphene Suisse AG has applied for delisting at the Vienna Stock Exchange
30-March-2020 / 18:35 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Roggwil, March 30, 2020 - Resaphene Suisse AG, ISIN CH0367465439, WKN A2JG91, today applied for delisting at the Vienna Stock Exchange and the last trading day will be April 30, 2020. In negotiations with investors, the listing on the stock exchange had proven to be an obstacle to the entry of private equity funds. The Board of Directors is now making a going private.
At the group level, the 1st quarter 2020 is currently developing into the best quarter in the company's history. This year, the FDA approval is to be obtained in order to bring the tinnitus therapy device tinniwell to the US market.
++ About Resaphene Suisse AG
Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company that was founded in 2015 and has been selling a tinnitus therapy device under the name tinniwell since 2016. The shares have been traded on the Vienna Stock Exchange in the Third Market segment since June 2018. Resaphene Deutschland GmbH in Constance and Resaphene UK Ltd. in London and Resaphene US LLC in the US act as further sales companies.
++ Contact for questions:
Resaphene Suisse AG
Investor Relations contact:
Ms. Anke Rauterkus (Chief Executive Officer)
30-March-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de